1. Home
  2. MDWD vs TCX Comparison

MDWD vs TCX Comparison

Compare MDWD & TCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • TCX
  • Stock Information
  • Founded
  • MDWD 2000
  • TCX 1992
  • Country
  • MDWD Israel
  • TCX Canada
  • Employees
  • MDWD N/A
  • TCX N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • TCX EDP Services
  • Sector
  • MDWD Health Care
  • TCX Technology
  • Exchange
  • MDWD Nasdaq
  • TCX Nasdaq
  • Market Cap
  • MDWD 184.8M
  • TCX 179.2M
  • IPO Year
  • MDWD 2014
  • TCX 1996
  • Fundamental
  • Price
  • MDWD $19.36
  • TCX $15.53
  • Analyst Decision
  • MDWD Strong Buy
  • TCX
  • Analyst Count
  • MDWD 1
  • TCX 0
  • Target Price
  • MDWD $25.00
  • TCX N/A
  • AVG Volume (30 Days)
  • MDWD 78.0K
  • TCX 23.4K
  • Earning Date
  • MDWD 03-20-2025
  • TCX 02-13-2025
  • Dividend Yield
  • MDWD N/A
  • TCX N/A
  • EPS Growth
  • MDWD N/A
  • TCX N/A
  • EPS
  • MDWD N/A
  • TCX N/A
  • Revenue
  • MDWD $19,720,000.00
  • TCX $356,135,000.00
  • Revenue This Year
  • MDWD $10.15
  • TCX $8.16
  • Revenue Next Year
  • MDWD $25.62
  • TCX N/A
  • P/E Ratio
  • MDWD N/A
  • TCX N/A
  • Revenue Growth
  • MDWD N/A
  • TCX 7.50
  • 52 Week Low
  • MDWD $11.04
  • TCX $14.50
  • 52 Week High
  • MDWD $24.00
  • TCX $26.48
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 55.03
  • TCX 41.13
  • Support Level
  • MDWD $19.59
  • TCX $14.50
  • Resistance Level
  • MDWD $20.62
  • TCX $16.58
  • Average True Range (ATR)
  • MDWD 0.83
  • TCX 0.57
  • MACD
  • MDWD 0.02
  • TCX -0.09
  • Stochastic Oscillator
  • MDWD 54.60
  • TCX 39.31

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About TCX Tucows Inc.

Tucows Inc is a corporate parent, allocating capital and providing efficient shared services to its three businesses. The Company offers Mobile Service Enabler (MSE) solutions, as well as professional services to other retail mobile providers. The Company is also a distributor of Internet services, including domain name registration, digital certificates, and email. It provides these services through an Internet-based distribution network of Internet Service Providers, web hosting companies, and other providers of Internet services to end-users. It operates in three segments: Ting, Wavelo, and Tucows Domains. It generates the majority of its revenue from Tucows Domains.

Share on Social Networks: